Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VUMERITY (Biogen Australia Pty Ltd)
Product name
VUMERITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
diroximel fumarate
Registration type
NCE/NBE
Indication
VUMERITY (enteric capsule) is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.